Dr Reddy's launches Pamorelin LA in India

On 3rd December, Dr Reddy's Laboratories launched Pamorelin (triptorelin) LA in India for the treatment of locally-advanced or metastatic, hormone-dependent prostate cancer.

Under the terms of an agreement with Debiopharm, Dr Reddy's acquired exclusive marketing and sales rights for Pamorelin LA Depot in India. The product is exported in bulk from Debio Recherche Pharmaceutique to Dr Reddy's. Pamorelin LA will be made available primarily to urologists and oncologists across India.

The one- and three-month formulations of triptorelin have been registered in most countries and are currently available under the names of Trelstar in North America, Decapeptyl/Pamorelin in Europe and Latin America and from now on, of Pamorelin in India. The six-month-formulation has been registered and is available in Europe and the US.

Agreement Information:
Agreement Status: New Date Announced: 7 Dec 2012
Date Last Reported: Duration:
Est Total Value: Investment To Date:
Agreement Type: Commercialisation
Generic / Brand Name: Pamorelin triptorelin Trelstar Decapeptyl
Therapeutic Area: Antineoplastic and Immunomodulating Agents
Indication: Cancer (prostate)
Techonology/Field: N/A
This article is tagged to:
Sector: Medical Devices
Geography: India, Switzerland

Enter your details to read the full article

By submitting this form you are acknowledging that you have read and understood our Privacy Policy.